Articles should be of interest to readers involved in all phases of clinical trials and with diverse levels of professional knowledge and expertise. Each month, about 14,000 clinical trials professionals in more than 40 countries receive Applied Clinical Trials. Clinical trials professionals write for Applied Clinical Trials to share their experience and expertise with their colleagues and to explain innovative approaches to common problems. Industry observers describe research trends and developments. Suppliers of clinical trials products and services who submit manuscripts need to take particular care to avoid any appearance that their article is an attempt to sell products or services.
Review articles can update readers on the state of the art or on industry trends.
ACT 101 articles should meet the needs of newcomers to clinical trials by explaining fundamental concepts and practices. The ACT 101 section includes reading lists and glossaries of regulatory, pharmaceutical, and clinical terms. Writers should include enough information so that readers can make independent judgments about how they might apply the technology to their own work. Letters to the Editor may respond to published articles, comment on issues of significance to clinical trials professionals, or open a debate on a topic of interest to ACT readers. Each letter should address one topic and be limited to 500 words.